TUESDAY, Dec. 8, 2020 (HealthDay Information) — New information launched Tuesday by the U.S. Meals and Drug Administration Vaccines and Associated Organic Merchandise Advisory Committee counsel that Pfizer’s two-dose COVID-19 vaccine works properly defending recipients in opposition to COVID-19.
The committee is scheduled to satisfy on Thursday to contemplate the Pfizer/BioNTech COVID-19 vaccine for emergency use authorization, CNBC reported.
In accordance with the FDA, the information from Pfizer’s COVID-19 vaccine trials had been “constant” with the company’s suggestions for an emergency use authorization. The information present that the vaccine gives safety after the primary dose and that two doses are “extremely efficient” in stopping COVID-19.
“As such, FDA has decided that the Sponsor has offered satisfactory data to make sure the vaccine’s high quality and consistency for authorization of the product underneath an EUA,” the company mentioned.
Right this moment, the UK started inoculating its residents with the Pfizer/BioNTech vaccine. America is anticipated to determine on the emergency approval of the vaccine earlier than the tip of the week, CNBC reported.